

## **KarXT for Schizophrenia: Effectiveness and Value**

Friday • February 9, 2024 • 10:00 AM to 4:00 PM ET

Virtual Event – Zoom Events

https://events.zoom.us/ev/Arkixslms6OZpl0fudX\_c5b\_h9J-fLeWPPKl\_7\_akA74oSJhW5NG~AkQgx60VHNGsgavAuLTVdMZjpI6W3H18a492jEZboY0SAhg6ZF4DmLoeeg

Time (ET)	Activity	
10:00am – 10:20am	Meeting Convened and Opening Remarks  Sarah K. Emond, MPP  President and CEO, ICER  Steven D. Pearson, MD, MSc  Special Advisor, ICER	
10:20am – 11:00am	Presentation of the Clinical Evidence  Jeff Tice, MD, Professor of Medicine University of California, San Francisco	
11:00am – 11:40am	Presentation of the Economic Model  Mel Whittington, PhD, MSc  Senior Fellow, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center	
11:40am – 12:05pm	Public Comments and Discussion	
12:05pm – 12:50pm	Lunch Break	
12:50pm – 1:50pm	New England CEPAC Vote on Clinical Effectiveness and Value	
1:50pm – 2:00pm	Break	
2:00pm – 3:30pm	Policy Roundtable	
3:30pm – 4:00pm	Reflections from New England CEPAC	
4:00pm	Meeting Adjourned	

Policy Roundtable Participant	Conflict of Interest
Kristin Khalaf Gillard, PharmD, PhD, Executive Director,	Dr. Gillard is a full-time employee of Karuna
HEOR, Karuna Therapeutics	Therapeutics.
Tony Grillo, PharmD, Vice President, Express Scripts	Dr. Grillo is a full-time employee of Express Scripts.
Steven Lamberti, MD, Professor of Psychiatry, URMC	No conflicts to disclose.
Arundati Nagendra, PhD, Director of Research and Scientific Affairs, Schizophrenia & Psychosis Action Alliance	S&PAA receives <25% funding from healthcare companies, including from Karuna Therapeutics.
Marc Pomper, Caregiver	No conflicts to disclose.
Marina Sehman, PharmD, CSP, Director, Clinical Pharmacy, IPD Analytics	Dr. Sehman is a full-time employee of IPD Analytics.
<b>Vinod Srihari, MD</b> , Professor of Psychiatry; Director, STEP Program, Yale School of Medicine	No conflicts to disclose.

ICER Staff and Consultants		
Sarah Emond, MPP, President and CEO, ICER	Grace Ham, BS, Program and Events Coordinator	
Yamaya Jean, MA, Program Manager, ICER	Avery McKenna, BS, Research Lead, ICER	
Becca Piltch, MPP, Program Manager, ICER	Steven Pearson, MD, MSc, Special Advisor, ICER	
Finn Raymond, BS, Research Assistant, ICER	David Rind, MD, MSc, Chief Medical Officer, ICER	
Jeff Tice, MD, Professor of Medicine, University of	Mel Whittington, PhD, MS, Senior Fellow Center for the	
California, San Francisco	Evaluation of Value and Risk in Health (CEVR), Tufts	
	Medical Center	
Abigail Wright, PhD, MSc, Research Lead, ICER		

<sup>\*</sup>No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of NE CEPAC		
Marthe Gold, MD, MPH, Senior Research Scholar, New		
York Academy of Medicine		
Rebecca Kirch, JD, EVP Policy and Programs, National		
Patient Advocate Foundation		
<b>Donald Kreis, MS, JD</b> , Patient Advocate, New Hampshire		
Office of the Consumer Advocate		
Stephanie Nichols, PharmD, MPH, BCPP, FCCP, Associate		
Professor, University of New England		
Jeanne Ryer, MSc, EdD, Director, NH Citizens Health		
Initiative		
Jason Wasfy, MD, Associate Professor, Harvard Medical		
School and Mass General Hospital		

<sup>\*</sup>No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.